A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200?mg/m2 and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma.

A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200?mg/m2 and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma. 2018 07; 59(7):1666-1671.

View in: PubMed

subject areas

Adult
Aged
Combined Modality Therapy
Drug Resistance, Neoplasm
Female
Hematopoietic Stem Cell Transplantation
Humans
Male
Maximum Tolerated Dose
Melphalan
Middle Aged
Multiple Myeloma
Recurrence
Retreatment
Survival Analysis
Transplantation Conditioning
Transplantation, Autologous
Treatment Outcome
Whole-Body Irradiation

authors with profiles

Matthew Koshy
Bulent Aydogan
Ralph R. Weichselbaum